Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases

Mucosal surfaces are the first site of infection for most infectious diseases and oral vaccination can provide protection as the first line of defense. Unlike systemic administration, oral immunization can stimulate cellular and humoral immune responses at both systemic and mucosal levels to induce...

Full description

Bibliographic Details
Main Authors: Seyed Davoud Jazayeri, Hui Xuan Lim, Kamyar Shameli, Swee Keong Yeap, Chit Laa Poh
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.682286/full
id doaj-44cdb92cb31746d090314effece41c24
record_format Article
spelling doaj-44cdb92cb31746d090314effece41c242021-06-02T06:57:48ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-06-011210.3389/fphar.2021.682286682286Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious DiseasesSeyed Davoud Jazayeri0Hui Xuan Lim1Kamyar Shameli2Swee Keong Yeap3Chit Laa Poh4Centre for Virus and Vaccine Research, Subang Jaya, MalaysiaCentre for Virus and Vaccine Research, Subang Jaya, MalaysiaMalaysia-Japan International Institute of Technology, Universiti Teknologi Malaysia, Kuala Lumpur, MalaysiaDepartment of Marine Biotechnology, China-Asean College of Marine Sciences, Xiamen University Malaysia, Sepang, MalaysiaCentre for Virus and Vaccine Research, Subang Jaya, MalaysiaMucosal surfaces are the first site of infection for most infectious diseases and oral vaccination can provide protection as the first line of defense. Unlike systemic administration, oral immunization can stimulate cellular and humoral immune responses at both systemic and mucosal levels to induce broad-spectrum and long-lasting immunity. Therefore, to design a successful vaccine, it is essential to stimulate the mucosal as well as systemic immune responses. Successful oral vaccines need to overcome the harsh gastrointestinal environment such as the extremely low pH, proteolytic enzymes, bile salts as well as low permeability and the low immunogenicity of vaccines. In recent years, several delivery systems and adjuvants have been developed for improving oral vaccine delivery and immunogenicity. Formulation of vaccines with nanoparticles and microparticles have been shown to improve antigen stability, availability and adjuvanticity as well as immunostimulatory capacity, target delivery and specific release. This review discusses how nanoparticles (NPs) and microparticles (MPs) as oral carriers with adjuvant characteristics can be beneficial in oral vaccine development.https://www.frontiersin.org/articles/10.3389/fphar.2021.682286/fullnanoparticlesmicroparticlesinfectious diseasesoral vaccinesvaccine carriers
collection DOAJ
language English
format Article
sources DOAJ
author Seyed Davoud Jazayeri
Hui Xuan Lim
Kamyar Shameli
Swee Keong Yeap
Chit Laa Poh
spellingShingle Seyed Davoud Jazayeri
Hui Xuan Lim
Kamyar Shameli
Swee Keong Yeap
Chit Laa Poh
Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases
Frontiers in Pharmacology
nanoparticles
microparticles
infectious diseases
oral vaccines
vaccine carriers
author_facet Seyed Davoud Jazayeri
Hui Xuan Lim
Kamyar Shameli
Swee Keong Yeap
Chit Laa Poh
author_sort Seyed Davoud Jazayeri
title Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases
title_short Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases
title_full Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases
title_fullStr Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases
title_full_unstemmed Nano and Microparticles as Potential Oral Vaccine Carriers and Adjuvants Against Infectious Diseases
title_sort nano and microparticles as potential oral vaccine carriers and adjuvants against infectious diseases
publisher Frontiers Media S.A.
series Frontiers in Pharmacology
issn 1663-9812
publishDate 2021-06-01
description Mucosal surfaces are the first site of infection for most infectious diseases and oral vaccination can provide protection as the first line of defense. Unlike systemic administration, oral immunization can stimulate cellular and humoral immune responses at both systemic and mucosal levels to induce broad-spectrum and long-lasting immunity. Therefore, to design a successful vaccine, it is essential to stimulate the mucosal as well as systemic immune responses. Successful oral vaccines need to overcome the harsh gastrointestinal environment such as the extremely low pH, proteolytic enzymes, bile salts as well as low permeability and the low immunogenicity of vaccines. In recent years, several delivery systems and adjuvants have been developed for improving oral vaccine delivery and immunogenicity. Formulation of vaccines with nanoparticles and microparticles have been shown to improve antigen stability, availability and adjuvanticity as well as immunostimulatory capacity, target delivery and specific release. This review discusses how nanoparticles (NPs) and microparticles (MPs) as oral carriers with adjuvant characteristics can be beneficial in oral vaccine development.
topic nanoparticles
microparticles
infectious diseases
oral vaccines
vaccine carriers
url https://www.frontiersin.org/articles/10.3389/fphar.2021.682286/full
work_keys_str_mv AT seyeddavoudjazayeri nanoandmicroparticlesaspotentialoralvaccinecarriersandadjuvantsagainstinfectiousdiseases
AT huixuanlim nanoandmicroparticlesaspotentialoralvaccinecarriersandadjuvantsagainstinfectiousdiseases
AT kamyarshameli nanoandmicroparticlesaspotentialoralvaccinecarriersandadjuvantsagainstinfectiousdiseases
AT sweekeongyeap nanoandmicroparticlesaspotentialoralvaccinecarriersandadjuvantsagainstinfectiousdiseases
AT chitlaapoh nanoandmicroparticlesaspotentialoralvaccinecarriersandadjuvantsagainstinfectiousdiseases
_version_ 1721407464737341440